GSK plc (GSK)
| Market Cap | 119.79B +55.7% |
| Revenue (ttm) | 43.97B +4.1% |
| Net Income | 7.69B +122.0% |
| EPS | 1.87 +123.2% |
| Shares Out | 4.01B |
| PE Ratio | 15.57 |
| Forward PE | 12.42 |
| Dividend | $1.75 (2.95%) |
| Ex-Dividend Date | Feb 20, 2026 |
| Volume | 7,469,641 |
| Open | 59.87 |
| Previous Close | 60.37 |
| Day's Range | 59.33 - 60.05 |
| 52-Week Range | 32.38 - 61.70 |
| Beta | 0.27 |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | Feb 4, 2026 |
About GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2025, GSK's revenue was 32.67 billion, an increase of 4.11% compared to the previous year's 31.38 billion. Earnings were 5.72 billion, an increase of 121.98%.
Financial numbers in GBP Financial StatementsNews
GSK's AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows
PHILADELPHIA--(BUSINESS WIRE)--GSK's AREXVY associated with reductions in certain RSV-related risks, real world study shows.
GSK: Post-Pivot Buoyancy Set To Continue After Strong 2025 (Upgrade)
GSK plc is a pharma worthy of a Buy rating, based on past performance and future prospects. In 2025, the company grew revenues by 7% and core EPS by 12%. GSK seems to have successfully pivoted into a ...
3 International Stocks to Buy for 2026
Plus, which countries and sectors look most attractive to invest in today. In this bonus episode of The Morning Filter podcast, host Susan Dziubinski talks with Morningstar chief Europe markets strate...
GSK plc (GSK) Q4 2025 Earnings Call Transcript
GSK plc (GSK) Q4 2025 Earnings Call Transcript
GSK's Specialty Medicines Drive Solid Results
The pharma company posted double-digit percentage growth in its immunology and inflammation, oncology and HIV portfolios for 2025, with sales of £32.67 billion.
GSK forecasts slower sales growth in 2026
GSK on Wednesday forecast sales growth to slow in 2026 in the first outlook presented by new CEO Luke Miels as the drugmaker shifts focus on expanding its pipeline to counter looming patent expiries f...
Wave Life Sciences Reclaims Rare Disease Drug From GSK, Targets Faster FDA Path
On Monday, Wave Life Sciences Ltd. (NASDAQ: WVE) said it regained full rights to WVE-006 from GSK Plc (NYSE: GSK).
Top FTSE 100 Index shares to watch: BT Group, Vodafone, Shell, GSK
The FTSE 100 Index continued its rally this week and was hovering near its all-time high as market participants reacted to the key earnings by some American companies and Lloyds Bank. It was trading ...
GSK Awards $2M in COiMMUNITY Initiative Grants to Help Close Vaccination Gaps, Commits $3M for 2026
PHILADELPHIA--(BUSINESS WIRE)-- #DiseaseEducation--GSK awards $2M in COiMMUNITY Initiative grants to help close vaccination gaps, commits $3M for 2026.
Forbion Announces Second Exit from Forbion Growth Fund III Following $2.2 Billion Acquisition of RAPT Therapeutics by GSK
NAARDEN, The Netherlands, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Forbion, a leading life sciences venture capital firm with deep roots in Europe, today announces that GSK (NYSE: GSK) has entered into a def...
GSK Announces Recipients of Linked by Lupus: Optimal Care Initiative Grants Nearing $1 Million
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) has announced the recipients of the Linked by Lupus: Optimal Care Initiative grant, awarding nearly $1 million to support national, state, and lo...
GSK to buy food allergy drug maker RAPT in $2.2bn deal
US-based biotech firm is developing treatment for allergies such as nuts, milk and eggs in children and adults
GSK announces $2.2 billion deal, targeting once-per-three-month food allergy drug
The growing scourge of food allergies drove U.K. heavyweight GSK to announce a $2.2 billion deal on Tuesday.
Alteogen Announces Exclusive License Agreement with Tesaro, a Subsidiary of GSK, for the Development of a Subcutaneous Formulation of Dostarlimab Enabled by Hybrozyme™ Technology
DAEJEON, South Korea, Jan. 20, 2026 /PRNewswire/ -- Alteogen Inc. (KOSDAQ: 196170) announced today that the company has entered into an exclusive license agreement with Tesaro, Inc., a subsidiary of G...
GSK to Acquire RAPT for $2.2 Billion to Bolster Food Allergy Treatments
The drugmaker said it agreed to pay RAPT shareholders $58 per share, with $1.9 billion upfront investment in cash.
GSK to buy RAPT Therapeutics for $2.2 billion
GSK said on Tuesday that it would acquire U.S.-based RAPT Therapeutics for $2.2 billion.
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
GSK plc (GSK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
GSK plc (GSK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
GSK Still Has Room To Run Despite Vaccine Cyclicality
GSK's growth is increasingly specialty-led (HIV, RI&I, oncology), not just vaccines. ViiV's long-acting injectables also tap into durable demand. Recent launches/approvals like Blenrep in r/r myeloma ...
Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate (ADC)
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced it has entered into a clinical trial collaboration with GSK plc (“GSK”, LSE/NYSE: GSK) to evaluate ivonescimab...
AnaptysBio seeks partial dismissal in GSK oncology unit dispute over drug royalty
AnaptysBio said on Thursday it filed a partial motion to dismiss a claim by GSK's oncology unit, which alleges the biotech breached their contract, escalating a legal dispute over royalties tied to sa...
GSK Licenses Noetik's AI Foundation Models in Anchor Partnership to Transform Cancer Therapeutic Research and Development
SAN FRANCISCO--(BUSINESS WIRE)-- #GSK--GSK licenses Noetik's AI foundation models in anchor partnership to transform cancer therapeutic research and development.
GSK/Ionis Partnered Investigational Drug Shows Strong Results In Large Hepatitis B Studies
Ionis Pharmaceuticals Inc. (NASDAQ: IONS) partner GSK Plc (NYSE: GSK) on Wednesday shared data from two pivotal Phase 3 studies, B-Well 1 and B-Well 2, of bepirovirsen, an investigational antisense ol...
GSK's chronic hepatitis B treatment meets main goal in key studies
GSK's experimental drug to treat chronic hepatitis B infection met the main goals in two closely watched studies, the drugmaker said on Wednesday, bringing the company a step closer to making a functi...
Exclusive: Drugmakers raise US prices on 350 medicines despite pressure from Trump
Drugmakers plan to raise U.S. prices on at least 350 branded medications including vaccines against COVID, RSV and shingles and blockbuster cancer treatment Ibrance, even as the Trump administration p...